BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-pharmaessentia-ropeginterferon-et-pdufa-aug2026@catalyst-calendar.local
DTSTAMP:20260720T200616Z
DTSTART:20260830T040000Z
DTEND:20260830T043000Z
SUMMARY:PharmaEssentia ropeginterferon ET适应症sBLA PDUFA窗口
DESCRIPTION:FDA将于2026年8月30日前后审评ropeginterferon alfa-2b-njft用于成人原发性血小板增多症的sBLA；事件影响骨髓增殖性肿瘤长期治疗和干扰素差异化定位。\\nImpact score: 60\\nExpected: FDA批准、CRL、标签限制或上市后研究要求。\\nAffected: 6446.TW(subject\, unknown\, score 76)\; INCY(peer\, mixed\, score 28)\; BMY(peer\, mixed\, score 22)\; IBB(etf\, unknown\, score 20)\\nSources: PharmaEssentia USA PDUFA press release: https://us.pharmaessentia.com/fda-confirms-a-pdufa-goal-date-of-august-30-2026-for-the-sbla-submission-of-ropeginterferon-alfa-2b-njft-in-essential-thrombocythemia-et/\\nPharmaEssentia ASCO/EHA data release: https://www.pharmaessentia.com/news/pharmaessentia-to-present-new-clinical-data-supporting-the-use-of-ropeginterferon-alfa-2b-in-essential-thrombocythemia-at-asco-and-eha-2026\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-pharmaessentia-ropeginterferon-et-pdufa-aug2026
CATEGORIES:fda\,TW\,FDA\,PDUFA\,hematology\,MPN
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: PharmaEssentia ropeginterferon ET适应症sBLA PDUFA窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: PharmaEssentia ropeginterferon ET适应症sBLA PDUFA窗口
END:VALARM
END:VEVENT
END:VCALENDAR